Patent: 8,318,666
Summary for Patent: 8,318,666
| Title: | Use of leptin to treat metabolic abnormalities associated with lipoatrophy |
| Abstract: | Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment. |
| Inventor(s): | Alexander M. DePaoli, Elif Arioglu Oral, Simeon I. Taylor, Abhimanyu Garg |
| Assignee: | Amgen Inc , University of Texas System , US Department of Health and Human Services |
| Application Number: | US13/103,294 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,318,666
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Chiesi Farmaceutici S.p.a. | MYALEPT | metreleptin | For Injection | 125390 | February 24, 2014 | 8,318,666 | 2031-05-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,318,666
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | E475094 | ⤷ Start Trial |
| Australia | 2002359288 | ⤷ Start Trial |
| Canada | 2464277 | ⤷ Start Trial |
| Cyprus | 1114326 | ⤷ Start Trial |
| Germany | 60237100 | ⤷ Start Trial |
| Denmark | 1444516 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
